Prenetics Global Limited (PRE)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Do Nothing: avgDollarVolume20 is $2.55M, below the $5.0M liquidity floor required for this 1–15 trading-day bullish strategy.
Company overview
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Fundamental
fairPrenetics shows strong revenue growth and liquidity but remains unprofitable and cash-flow negative.
Prenetics is showing outsized revenue growth (latest quarter revenue about $36M with ~65% gross margin) while remaining unprofitable and cash-flow negative (TTM net margin about -62% and negative free-cash-flow yield). Liquidity appears solid and debt is minimal, which reduces near-term solvency risk, but execution and regulatory risks remain elevated. Overall fundamentalScore: 3/5 (fast growth, still speculative).
Sentiment
fairRecent bullish catalysts are tempered by mixed media sentiment and indeterminate retail signals.
Prenetics has two recent, company-announced bullish catalysts (record Q1 2026 update/raised guidance on 2026-06-10 and a board appointment on 2026-06-04), but third-party coverage over the last ~14d is mixed and less bullish than the 30–90d baseline; retail sentiment is indeterminate due to Reddit rate limits. Red-Flag Screen clean (no cases or regulator-confirmed investigations surfaced).
Technical
fairThe stock is in an uptrend, with a pullback to support providing a potential entry point.
PRE is in an early repair phase after the early-July flush: the close is back above EMA9, EMA21, SMA50, and SMA200, RSI14 has recovered to neutral, and Williams %R has lifted out of oversold territory. The score stays mixed because price still sits below the SMA20 and today's VWAP, while MACD remains below both zero and its signal line.
You’re looking at 2026-07-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.